Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors

NCT00420485 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: gimatecan

Sponsor

Novartis Pharmaceuticals